Zoetis today announced the launch of Vanguard® CIV H3N2/H3N8,
the latest vaccine in the company’s canine influenza virus (CIV)
portfolio. The new bivalent vaccine helps protect dogs against two
strains of the virus known to be circulating in the U.S., CIV H3N2
and CIV H3N8. CIV is a severe and highly contagious respiratory
infection that has caused many serious disease outbreaks in 38
states across the country.1 The United States Department of
Agriculture (USDA) granted Zoetis a license for this vaccine in
June 2017.
“Zoetis is committed to helping protect dogs from all known
strains of canine influenza virus, and our new Vanguard CIV
H3N2/H3N8 vaccine is the most recent example of our innovation in
this area,” said Tara L. Bidgood, DVM, PhD, DACVCP, Executive
Director, U.S. Companion Animal Division Veterinary Professional
Services at Zoetis. “We are pleased to offer veterinarians this
vaccine, which is backed by outstanding safety and efficacy data,
so that they can help protect their canine patients from this
potentially deadly virus.”
In a key efficacy study, dogs receiving the Vanguard CIV
H3N2/H3N8 vaccine were protected from disease after CIV H3N2
exposure and also appeared to have a reduced number of days that
dogs were capable of spreading CIV H3N2 virus.2,3,4
The safety of the Vanguard CIV H3N2/H3N8 vaccine was
demonstrated in a field study involving both client-owned dogs and
dogs from commercial breeding facilities, where no significant
adverse events were observed after vaccination.5
“Dogs that attend daycare, visit the dog park or stay at
boarding facilities are all at risk for contracting either strain
of CIV,” said Stephan Carey, DVM, PhD, DACVIM, Assistant Professor,
Small Animal Clinical Sciences at Michigan State University College
of Veterinary Medicine and Past President of The Veterinary
Comparative Respiratory Society.* “There is no way to predict
whether it will be CIV H3N2 or CIV H3N8 that infects your area, so
it is better to help protect against both strains; this bivalent
vaccine allows you do to that efficiently.”
About Canine Influenza Virus
There are two prevalent strains of canine influenza virus in the
United States: CIV H3N8 and CIV H3N2. Dogs need vaccinations
against both to help provide complete protection. CIV H3N8 was
first identified in racing greyhounds in Florida in 2004. CIV H3N2
was first detected in the United States in March 2015 in Chicago.
In response to the Chicago CIV H3N2 outbreak, Zoetis researchers
immediately prioritized development of a vaccine and received the
first conditional license from the USDA for a CIV H3N2 vaccine in
November 2015. Vanguard CIV H3N2 received full licensure in
2016.
Most commonly, canine influenza virus is spread through direct
contact with respiratory secretions from infected dogs. It can also
be spread when dogs come into contact with contaminated objects
(e.g., toys, clothing, communal water bowls, etc.) and remains
viable for up to 48 hours.6 After a dog is infected, there is a
pre-clinical phase during which the dog still appears healthy, but
is capable of spreading the virus to other dogs and into the
environment. The severity of the infection varies; in some cases,
it can cause severe pneumonia and even death.
The American Veterinary Medical Association (AVMA) cautions that
dogs that are frequently in contact with other dogs are at
especially high risk of infection.7 Pet owners should isolate their
dogs from any dog that is coughing or shows signs of respiratory
illness, and should consult a veterinarian. As with other
infectious diseases, the AVMA also advises pet owners to take extra
precautions with puppies, elderly or pregnant dogs, and dogs that
are immunocompromised. In addition, the AVMA suggests that pet
owners speak with their veterinarian regarding both their dog’s
risk for canine influenza and the appropriateness of
vaccination.7
As more dogs across the United States are vaccinated, underlying
immunity to CIV should increase in the canine population. This can
help to decrease the capability of both strains of the virus to
spread through the population and thereby help prevent
outbreaks.
To learn more about Vanguard CIV H3N2/H3N8, visit
www.vanguardciv.com.
About Zoetis
Zoetis is the leading animal health company, dedicated to
supporting its customers and their businesses. Building on more
than 60 years of experience in animal health, Zoetis discovers,
develops, manufactures and markets veterinary vaccines and
medicines, complemented by diagnostic products, genetic tests,
biodevices and a range of services. Zoetis serves veterinarians,
livestock producers and people who raise and care for farm and
companion animals with sales of its products in more than 100
countries. In 2016, the company generated annual revenue of $4.9
billion with approximately 9,000 employees. For more information,
visit www.zoetis.com.
References:
1 Data on file, Study Report No. BLOR
40813. Data was not obtained from all national and regional
veterinary laboratories. We cannot confirm the percentage of actual
cases.
2 Dogs were considered to have disease as
a result of CIV H3N2 infection if they had two or more clinical
signs observed on two or more consecutive days.
3 Dogs were only evaluated for shedding
for six days after challenge.
4 Data on file, Study Report No.
B862R-US-16-226, Zoetis Inc.
5 Data on file, Study Report No.
B961R-US-16-225, Zoetis Inc.
6 Canine influenza. American Veterinary
Medical Association.
https://www.avma.org/KB/Resources/Reference/Pages/Canine-Influenza-Backgrounder.aspx.
Accessed May 22, 2017.
7 Canine influenza FAQ: questions,
answers, and interim guidelines. American Veterinary Medical
Association. https://www.avma.org/KB/Resources/FAQs/Pages/Control-of-Canine-Influenza-in-Dogs.aspx?PF=1.
Accessed May 22, 2017.
* Dr. Stephan Carey is a consultant to Zoetis.
All trademarks are the property of Zoetis Services LLC or a
related company or a licensor unless otherwise noted. ©2017 Zoetis
Services LLC. All rights reserved. SAB-00595
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171212005416/en/
ZoetisColleen White,
973-822-7203colleen.white@zoetis.comorArcher MalmoLindsey Goodman,
706-201-6721lgoodman@archermalmo.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Sep 2023 to Sep 2024